ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
6,040.53
-0.50%
US Tech 100
20,778.00
-0.69%
다우존스 지수
44,544.66
-0.75%
Bitcoin
101,944.41
-0.45%
Registration Strip Icon for alerts 실시간 알림, 사용자 정의 포트폴리오 및 시장 동향을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Prevail Therapeutics Inc (PRVL) 시세

Prevail Therapeutics Inc

Prevail Therapeutics Inc (PRVL)

Porvair PLC
Porvair PLC
Porvair PLC
23.00
0.00
(0.00%)
마감 02 2월 6:00AM
15분 지연
0.00
0.00
(0.00%)
시간외 거래: -
15분 지연

개인 투자자를 위한 전문가급 도구.

프리미엄

주요 통계 및 세부정보

가격
23.00
매수가
24.00
매도가
23.00
거래량
-
0.00 일간 변동폭 0.00
0.00 52주 범위 0.00
전일 종가
23.00
개장가
-
최근 거래 시간
마지막 거래 시간
평균 볼륨(3m)
-
재정 규모
-
VWAP
-

PRVL 최신 뉴스

추가 뉴스

Lilly Completes Acquisition of Prevail Therapeutics

Lilly Completes Acquisition of Prevail Therapeutics PR Newswire INDIANAPOLIS, Jan. 22, 2021 INDIANAPOLIS, Jan. 22, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the...

22 1월 2021
PR Newswire (US)

Lilly Announces Agreement to Acquire Prevail Therapeutics

Lilly Announces Agreement to Acquire Prevail Therapeutics Acquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden...

15 12월 2020
PR Newswire (US)

Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of...

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...

11 12월 2020
GlobeNewswire Inc.

Prevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal Dementia

NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...

30 11월 2020
GlobeNewswire Inc.

Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR001

NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...

19 11월 2020
GlobeNewswire Inc.

Prevail Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights

Patient Dosing Continues in the Phase 1/2 PROPEL Trial of PR001 for Parkinson’s Disease with GBA1 Mutations Phase 1/2 PROVIDE Trial of PR001 for Type 2 Gaucher Disease and Phase 1/2 PROCLAIM...

13 11월 2020
GlobeNewswire Inc.

Prevail Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...

10 11월 2020
GlobeNewswire Inc.

Prevail Therapeutics Announces Decisive Victory in Arbitration Brought by Alector against Prevail’s CEO

NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...

02 11월 2020
GlobeNewswire Inc.

Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Neuronopathic Gaucher Disease

NEW YORK, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...

27 10월 2020
GlobeNewswire Inc.

Prevail Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with...

26 9월 2020
GlobeNewswire Inc.
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

PRVL - Frequently Asked Questions (FAQ)

What is the current Prevail Therapeutics share price?
The current share price of Prevail Therapeutics is US$ 23.00
What is the 1 year trading range for Prevail Therapeutics share price?
Prevail Therapeutics has traded in the range of US$ 0.00 to US$ 0.00 during the past year

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
TCTMTCTM Kids IT Education Inc
US$ 0.764
(321.87%)
729.72M
REBNReborn Coffee Inc
US$ 3.31
(63.05%)
55.54M
FCUVFocus Universal Inc
US$ 5.87
(56.62%)
1.73M
SOPASociety Pass Inc
US$ 1.54
(56.50%)
13.82M
CYCNCyclerion Therapeutics Inc
US$ 3.92
(54.33%)
82.39M
ENVBEnveric Biosciences Inc
US$ 2.0899
(-46.41%)
1.58M
NIVFNewGenIvf Group Ltd
US$ 0.1489
(-42.51%)
14.91M
GLSTGlobal Star Acquisition Inc
US$ 8.83
(-39.10%)
23.93k
PRPHProPhase Labs Inc
US$ 0.2633
(-38.02%)
900.48k
SPGCSacks Parente Golf Inc
US$ 0.5601
(-37.86%)
7.42M
TCTMTCTM Kids IT Education Inc
US$ 0.764
(321.87%)
729.72M
NVDANVIDIA Corporation
US$ 120.07
(-3.67%)
388.54M
RIMEAlgorhythm Holdings Inc
US$ 0.02565
(5.12%)
338.75M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0355
(-11.25%)
236.29M
CLEUChina Liberal Education Holdings Ltd
US$ 0.1938
(30.77%)
234.8M

토론

전체 피드 보기
게시물을 찾을 수 없습니다

최근 히스토리

NASDAQ
PRVL
Prevail Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2025 ADVFN PLC - 모든 권리 보유

광고 제거

광고 없는 경험을 위해 가입하세요

광고 없음

지금 사용해 보세요

광고 유지